Alzheimer's Disease Trial, Recruiting NCT06095063 Sponsor: Rotman Research Institute at Baycrest Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06095063
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a close family member (parent, sibling, or child), living or deceased, who has been diagnosed with or probably had Alzheimer's disease that developed later in life
  • People who have noticed changes in their own memory and are concerned about those changes
  • People who score 26 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA)
  • People who are willing to give their formal agreement to take part in the study
  • People who are able to follow the treatment schedule throughout the study
  • People whose medications have been the same for at least 2 months and are not expected to change during the study (if taking any medications)
  • People who pass a safety screening questionnaire related to the treatment used in this trial (a type of brain stimulation called TMS)
  • People who have a family member, friend, or carer who is able to fill in questionnaires about the participant during the study

Who may not be able to join:

  • People who have any metal implants in their head (outside the mouth), such as ear implants, brain stimulators, or aneurysm clips
  • People who have, or have had, increased pressure in the brain, which may raise the risk of seizures
  • People who have a cardiac pacemaker
  • People who have an implanted medication pump
  • People who have a central venous line (a type of tube inserted into a large vein)
  • People who have a significant heart condition
  • People who currently have depression, or have a history of certain mental health conditions including psychotic disorders, bipolar disorder, eating disorders, obsessive compulsive disorder, post-traumatic stress disorder, or a type of dementia other than Alzheimer's disease
  • People who have used alcohol or drugs problematically in the last 6 months
  • People who have had a stroke or have other known lesions (areas of damage) in the brain
  • People who have a personal history of epilepsy
  • People who have a family history of epilepsy
  • Women who are pregnant or breastfeeding
  • People who have had an abnormal brain MRI scan
  • People who have significant hearing loss that requires hearing aids
  • People who have an untreated thyroid condition (either underactive or overactive thyroid)
  • People who have other reasons they cannot safely receive TMS (confirm with trial site)
  • People who have unstable medical conditions
  • People who have regularly used benzodiazepines (a type of sedative or anxiety medication) or other sleep medications within 2 weeks of being enrolled in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Linda Mah, Baycrest Rotman Research Institute

Phone: 416-785-2500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Rotman Research Institute at Baycrest
Registry
ClinicalTrials.gov
Start date
15 November 2023
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Percentage of scheduled treatment sessions that are attended by study participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov